Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease

American Journal of Surgical Pathology

Volumn 38, Issue 4, 2014, Pages 448-460

  Kadota, Kyuichi ^a,b,e   Villena Vargas, Jonathan ^a   Yoshizawa, Akihiko ^f   Motoi, Noriko ^g   Sima, Camelia S ^c   Riely, Gregory J ^d   Rusch, Valerie W ^a   Adusumilli, Prasad S ^a,b   Travis, William D ^b  

^a Thoracic Service   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Department of Epidemiology and Biostatistics ^*  (United States)

^d Thoracic Oncology Service   (United States)

^e KAGAWA UNIVERSITY   (Japan)

^f SHINSHU UNIVERSITY HOSPITAL   (Japan)

^g CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Adenocarcinoma in situ; Lepidic; Lung adenocarcinoma; Minimally invasive adenocarcinoma; Recurrence

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOMA IN SITU; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84897027621     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000134     Document Type: Article

References (57)

1. Travis W, Brambilla E, Muller-Hermelink H, et al. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press; 2004.
2. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
3. Jones KD. Whence Lepidic? Arch Pathol Lab Med. 2013. [Epub ahead of print].
4. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
5. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: Histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004;28: 198-206.
6. Vazquez M, Carter D, Brambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: Histopathologic features and their prognostic implications. Lung Cancer. 2009;64:148-154.
7. Koike T, Togashi K, Shirato T, et al. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg. 2009;88:1106-1111.
8. Borczuk AC, Qian F, Kazeros A, et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma. Am J Surg Pathol. 2009;33:462-469.
9. Yim J, Zhu LC, Chiriboga L, et al. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol. 2007;20:233-241.
10. Maeshima AM, Tochigi N, Yoshida A, et al. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: A reliable prognostic indicator. J Thorac Oncol. 2010;5:333-339.
11. Lee HY, Han J, Lee KS, et al. Lung adenocarcinoma as a solitary pulmonary nodule: Prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer. 2009;66:379-385.
12. Yokose T, Suzuki K, Nagai K, et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29:179-188.
13. Lin DM, Ma Y, Zheng S, et al. Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma. Histol Histopathol. 2006;21:627-632.
14. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung adenocarcinoma in resected specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137:685-705.
15. Nakata M, Sawada S, Saeki H, et al. Prospective study of thoracoscopic limited resection for ground-glass opacity selected by computed tomography. Ann Thorac Surg. 2003;75:1601-1605; discussion 5-6.
16. Suzuki K, Asamura H, Kusumoto M, et al. "Early" peripheral lung cancer: Prognostic significance of ground glass opacity on thinsection computed tomographic scan. Ann Thorac Surg. 2002; 74:1635-1639.
17. Takashima S, Li F, Maruyama Y, et al. Discrimination of subtypes of small adenocarcinoma in the lung with thin-section CT. Lung Cancer. 2002;36:175-182.
18. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
19. Aberle DR, Berg CD, Black WC, et al. The National Lung Screening Trial: Overview and study design. Radiology. 2011; 258:243-253.
20. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868-874.
21. Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009:253-270.
22. Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol. 2010;34:1155-1162.
23. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653-664.
24. Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012;25: 1117-1127.
25. Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: Tumor interleukin-receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/ CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31:490-498.
26. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer. 2010;116:659-669.
27. Asamura H, Ando M, Matsuno Y, et al. Histopathologic prognostic factors in resected adenocarcinomas: Is nuclear DNA content prognostic? Chest. 1999;115:1018-1024.
28. Kurokawa T, Matsuno Y, Noguchi M, et al. Surgically curable "early" adenocarcinoma in the periphery of the lung. Am J Surg Pathol. 1994;18:431-438.
29. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934-944.
30. Baak JP. Mitosis counting in tumors. Hum Pathol. 1990;21:683-685.
31. Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol. 2012;25:260-271.
32. Chappell R. Competing risk analyses: How are they different and why should you care? Clin Cancer Res. 2012;18:2127-2129.
33. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012; 18:2301-2308.
34. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
35. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6:1496-1504.
36. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013;81:371-376.
37. Gu J, Lu C, Guo J, et al. Prognostic significance of the IASLC/ATS/ ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol. 2013; 107:474-480.
38. Woo T, Okudela K, Mitsui H, et al. Prognostic value of the IASLC/ ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int. 2012;62:785-791.
39. Zhang J, Wu J, Tan Q, et al. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: A clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS Classification. J Thorac Oncol. 2013;8:1196-1202.
40. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30:1438-1446.
41. von der Thusen JH, Tham YS, Pattenden H, et al. Prognostic significance of predominant histologic pattern and nuclear grade in resected adenocarcinoma of the lung: Potential parameters for a grading system. J Thorac Oncol. 2013;8:37-44.
42. Nitadori JBA, Kadota K, Sima CS, et al. Impact of micropapillary histologic subtype in selecting limited resection vs. lobectomy for lung adenocarcinoma r2 cm. J Natl Cancer Inst. 2013;105: 1212-1220.
43. Honda T, Kondo T, Murakami S, et al. Radiographic and pathological analysis of small lung adenocarcinoma using the new IASLC classification. Clin Radiol. 2013;68:e21-e26.
44. Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter study. J Thorac Cardiovasc Surg. 2012;143:607-612.
45. Yanagawa N, Shiono S, Abiko M, et al. New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol. 2013;8:612-618.
46. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
47. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
48. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311.
49. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006;12:1647-1653.
50. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865.
51. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest. 2005;128:317-321.
52. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med. 1999;18:695-706.
53. Kadota K, Nitadori J, Sarkaria IS, et al. Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. Cancer. 2013;119: 931-938.
54. Kadota K, Colovos C, Suzuki K, et al. FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol. 2012;19:3598-3605.
55. Urer HN, Kocaturk CI, Gunluoglu MZ, et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg. 2013. [Epub ahead of print].
56. Weissferdt A, Kalhor N, Marom EM, et al. Early-stage pulmonary adenocarcinoma (T1N0M0): A clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience. Mod Pathol. 2013;26:1065-1075.
57. Xu L, Tavora F, Battafarano R, et al. Adenocarcinomas with prominent lepidic spread: Retrospective review applying new classification of the American Thoracic Society. Am J Surg Pathol. 2012;36:273-282.